Royal Bank Of Canada Morphic Holding, Inc. Transaction History

Royal Bank Of Canada

$422 Billion
Q1 2024

A detailed history of Royal Bank Of Canada transactions in Morphic Holding, Inc. stock. As of the latest transaction made, Royal Bank Of Canada holds 1,894 shares of MORF stock, worth $64,528. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,894

Previous 12,429 84.76%

Holding current value

$64,528

Previous $358,000 81.56%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$26.64 - $40.31 $280,652 - $424,665	-10,535 Reduced 84.76%	1,894 $66,000
Q4 2023 Feb 14, 2024	BUY	$19.95 - $31.0 $132,108 - $205,282	6,622 Added 114.03%	12,429 $358,000
Q3 2023 Nov 14, 2023	BUY	$21.33 - $59.42 $50,210 - $139,874	2,354 Added 68.17%	5,807 $133,000
Q2 2023 Aug 14, 2023	BUY	$34.33 - $62.11 $46,139 - $83,475	1,344 Added 63.73%	3,453 $197,000
Q1 2023 May 15, 2023	SELL	$26.01 - $48.69 $112,987 - $211,509	-4,344 Reduced 67.32%	2,109 $79,000

Q4 2022 Feb 14, 2023	BUY	$24.14 - $30.37 $132,166 - $166,275	5,475 Added 559.82%	6,453 $172,000
Q3 2022 Nov 14, 2022	SELL	$22.23 - $33.37 $4,734 - $7,107	-213 Reduced 17.88%	978 $28,000
Q2 2022 Aug 15, 2022	SELL	$19.74 - $43.01 $85,533 - $186,362	-4,333 Reduced 78.44%	1,191 $26,000
Q1 2022 May 16, 2022	SELL	$36.25 - $52.02 $200,353 - $287,514	-5,527 Reduced 50.01%	5,524 $222,000
Q4 2021 Feb 14, 2022	SELL	$43.27 - $65.72 $506,259 - $768,924	-11,700 Reduced 51.43%	11,051 $524,000
Q3 2021 Nov 15, 2021	SELL	$53.61 - $67.5 $71,515 - $90,045	-1,334 Reduced 5.54%	22,751 $1.29 Million
Q2 2021 Aug 16, 2021	BUY	$45.13 - $64.99 $1.09 Million - $1.57 Million	24,085 New	24,085 $1.38 Million

Others Institutions Holding MORF

# of Institutions

142

Shares Held

37.9M

Call Options Held

13.5K

Put Options Held

190K

View Full List

About Morphic Holding, Inc.

Ticker MORF
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,477,100
Market Cap $1.31B
Description
Morphic Holding, Inc., a biopharmaceutical company, discovers and develops oral small-molecule integrin therapeutics for the treatment of autoimmune, cardiovascular, metabolic diseases, as well as fibrosis and cancer. Its lead product candidates are MORF-057, an a4ß7-specific integrin inhibitor affecting inflammation that is in Phase 1 clinical ...

More about MORF

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Royal Bank Of Canada, based on Form 13F filings with the SEC.

News

Stay updated on Royal Bank Of Canada with notifications on news.

Account

Royal Bank Of Canada Morphic Holding, Inc. Transaction History